Applied Therapeutics Says FDA Unable To Approve Govorestat NDA Due To Clinical Deficiencies; Expects To Submit An NDA Early In Q1 Of 2025

BenzingaNov 27 16:16 ET

Applied Therapeutics Receives Complete Response Letter From U.S. FDA Regarding New Drug Application For Govorestat For Classic Galactosemia

BenzingaNov 27 16:11 ET

Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs

Seeking AlphaNov 26 13:03 ET

Top 3 Health Care Stocks That May Dip This Month

BenzingaNov 25 08:29 ET

Abeona Therapeutics Analyst Ratings

BenzingaNov 25 07:44 ET · Ratings

Novo Semaglutide Data in MASH Could Negatively Impact Madrigal's Rezdiffra

Seeking AlphaNov 20 14:02 ET